Figure 2 | Scientific Reports

Figure 2

From: The role of graft T-cell size in patients receiving alemtuzumab serotherapy for non-malignant disorders: results of an institutional protocol

Figure 2

(a) Incidence and Grade of GvHD in all patients. 2 (b) GvHD incidence and grade in patients with low-GvHD risk graft versus high-GvHD risk graft is shown. No statistically significant difference was seen. 2 (c) GvHD incidence was high in patients receiving ≥ 500 million T cells compared to those who received < 500 million T cells. 2 (d) Days after transplant when onset and resolution of CMV viraemia occurred is shown. The majority of patients had predictable CMV viraemia with less than 30 days of viraemia. Two patients shown in grey dots had prolonged viraemia. 2 (e) CD4+ and CD8 + T cells at the onset and resolution of CMV viraemia are shown. Patients receiving high dose alemtuzumab are shown as squares with black borders. CD4+ and CD8 + T-cell responses were observed at the resolution of viraemia irrespective of the dose of alemtuzumab.

Back to article page